Cargando…

Advances in CXCR7 Modulators

CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancer...

Descripción completa

Detalles Bibliográficos
Autor principal: Lounsbury, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169404/
https://www.ncbi.nlm.nih.gov/pubmed/32098047
http://dx.doi.org/10.3390/ph13020033
_version_ 1783523782613270528
author Lounsbury, Nicole
author_facet Lounsbury, Nicole
author_sort Lounsbury, Nicole
collection PubMed
description CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels.
format Online
Article
Text
id pubmed-7169404
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71694042020-04-20 Advances in CXCR7 Modulators Lounsbury, Nicole Pharmaceuticals (Basel) Review CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels. MDPI 2020-02-21 /pmc/articles/PMC7169404/ /pubmed/32098047 http://dx.doi.org/10.3390/ph13020033 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lounsbury, Nicole
Advances in CXCR7 Modulators
title Advances in CXCR7 Modulators
title_full Advances in CXCR7 Modulators
title_fullStr Advances in CXCR7 Modulators
title_full_unstemmed Advances in CXCR7 Modulators
title_short Advances in CXCR7 Modulators
title_sort advances in cxcr7 modulators
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169404/
https://www.ncbi.nlm.nih.gov/pubmed/32098047
http://dx.doi.org/10.3390/ph13020033
work_keys_str_mv AT lounsburynicole advancesincxcr7modulators